{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:57:04Z","timestamp":1777859824160,"version":"3.51.4"},"reference-count":6,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Background: Despite the effectiveness of the TRIO regimen in maintaining viral suppression, as seen in the ANRS 139 TRIO trial, one drawback is the high pill burden. However, with the development of newer antiretrovirals, this regimen can be simplified. The combination of both co-formulated darunavir\/cobicistat and dolutegravir\/rilpivirine keeps the integrity of the TRIO regimen while decreasing daily pill count from 12 to 2 tablets daily. The purpose of this case series is to demonstrate the efficacy of this regimen as there is a current lack of data. Methods: This case series included patients with no resistance to dolutegravir, rilpivirine, or darunavir, who were switched to the modified TRIO regimen between June 1st 2018 to June 1st 2022. The primary outcome was the proportion of patients with plasma HIV-RNA levels &lt;50 copies\/mL by 24\u00a0weeks. Results: At week 24, all patients (n = 9) had a HIV-RNA &lt;50 copies\/mL. At week 48, one patient did not have a VL available. However, out of the remaining 8 patients, all maintained an HIV-RNA of &lt;50 copies\/mL at week 48. Conclusion: HIV-RNA levels remained suppressed when patients were switched to the modified TRIO regimen. In addition, the pill burden was reduced which can add to overall patient satisfaction.<\/jats:p>","DOI":"10.1177\/08971900241247618","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T07:34:27Z","timestamp":1714376067000},"page":"1400-1404","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real World Data of Viral Suppression With Darunavir\/Cobicistat and Dolutegravir\/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-9564","authenticated-orcid":false,"given":"Preethi S.","family":"Samuel","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA"},{"name":"Department of Pharmacy, Staten Island University Hospital, Staten Island, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9052-1287","authenticated-orcid":false,"given":"Folake","family":"Olaleye","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA"},{"name":"Department of Pharmacy, The Brooklyn Hospital Center, Brooklyn, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA"},{"name":"Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University (LIU Pharmacy), Brooklyn, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Program for AIDS Treatment and Health (PATH) Center, The Brooklyn Hospital Center, Brooklyn, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"bibr1-08971900241247618","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Washington, DC: Department of Health and Human Services. 2023. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 2\/20\/2023."},{"key":"bibr2-08971900241247618","unstructured":"Pan American Health Organization. HIV Drug Resistance - PAHO\/WHOPan American Health Organization. Washington, DC: 2017. Accessed June 24, 2023. https:\/\/www.paho.org\/en\/topics\/hiv-drug-resistance"},{"key":"bibr3-08971900241247618","unstructured":"NationalTreatment AIDS Advocacy Project. Perspectives in HIV Drug Resistance. 2006. Accessed February 20, 2023. https:\/\/www.natap.org\/2006\/HIV\/071906_02.htm"},{"key":"bibr4-08971900241247618","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"bibr5-08971900241247618","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824bb720"},{"key":"bibr6-08971900241247618","volume-title":"StatPearls","author":"Li R","year":"2023"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241247618","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241247618","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241247618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:26Z","timestamp":1777509506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241247618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/08971900241247618"],"URL":"https:\/\/doi.org\/10.1177\/08971900241247618","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}